Implant placement guide

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

FIG. 1 is a perspective view of our design for an implant placement guide;

FIG. 2 is a first side view of the design for the implant placement guide of FIG. 1;

FIG. 3 is a second side view of the design for the implant placement guide of FIG. 1;

FIG. 4 is a front view of the design for the implant placement guide of FIG. 1;

FIG. 5 is a back view of the design for the implant placement guide of FIG. 1;

FIG. 6 is a top view for the design for the implant placement guide of FIG. 1; and,

FIG. 7 is a bottom view for the design of the implant placement guide of FIG. 1.

Claims

The ornamental design for an implant placement guide, as shown and described.

Referenced Cited
U.S. Patent Documents
1655158 January 1928 Muir
2110208 March 1938 Eggert
2168437 August 1939 Buercklin
2531724 November 1950 Cevasco
2643653 June 1953 Heidrich
D179537 January 1957 Floyd
3016895 January 1962 Sein
3025991 March 1962 Gillon
3122162 February 1964 Sands
35232906 August 1970 Vrancken et al.
3538916 November 1970 Groff et al.
3620216 November 1971 Szymanski
3625214 December 1971 Higuchi
3632768 January 1972 Bergy et al.
3669104 June 1972 Wyatt et al.
3691090 September 1972 Kitajima et al.
D226915 May 1973 Huggins
3732865 May 1973 Higuchi et al.
3737337 June 1973 Sonnoring et al.
3766915 October 1973 Rychlik
3773919 November 1973 Boswell et al.
3797492 March 1974 Place
3869549 March 1975 Geller
3891570 June 1975 Fukushima et al.
D236035 July 1975 Ciencewicki
3960757 June 1, 1976 Morishita et al.
3987790 October 26, 1976 Eckenhoff et al.
3995631 December 7, 1976 Higuchi et al.
3995632 December 7, 1976 Nakano et al.
4008719 February 22, 1977 Theeuwes et al.
4034756 July 12, 1977 Higuchi et al.
4078060 March 7, 1978 Benson et al.
4105030 August 8, 1978 Kercso
4111201 September 5, 1978 Theeuwes
4111202 September 5, 1978 Theeuwes
4111203 September 5, 1978 Theeuwes
4203439 May 20, 1980 Theeuwes
4211771 July 8, 1980 Witkowski et al.
4221862 September 9, 1980 Naito et al.
4223674 September 23, 1980 Fluent et al.
4243030 January 6, 1981 Lynch et al.
D258837 April 7, 1981 Spranger
D259458 June 9, 1981 Fuller
4305927 December 15, 1981 Theeuwes et al.
4310516 January 12, 1982 Chang et al.
4340054 July 20, 1982 Michaels
4350271 September 21, 1982 Eckenhoff
4373527 February 15, 1983 Fischell
4376118 March 8, 1983 Daher
4384975 May 24, 1983 Fong
4389330 June 21, 1983 Tice et al.
D271990 December 27, 1983 Lyne
4439196 March 27, 1984 Higuchi
4444498 April 24, 1984 Heinemann
4451253 May 29, 1984 Harman
4455143 June 19, 1984 Theeuwes et al.
4455145 June 19, 1984 Theeuwes
4474572 October 2, 1984 McNaughton et al.
4530840 July 23, 1985 Tice et al.
4552561 November 12, 1985 Eckenhoff et al.
4588614 May 13, 1986 Lauchenauer
4594108 June 10, 1986 Greminger, Jr. et al.
4597753 July 1, 1986 Turley
4609374 September 2, 1986 Ayer
4639244 January 27, 1987 Rizk et al.
4655462 April 7, 1987 Balsells
4673405 June 16, 1987 Guittard et al.
4675184 June 23, 1987 Hasegawa et al.
4695623 September 22, 1987 Stabinsky
4727138 February 23, 1988 Goeddel et al.
4734284 March 29, 1988 Terada et al.
4737437 April 12, 1988 Gutseil, Jr. et al.
4743449 May 10, 1988 Yoshida et al.
4753651 June 28, 1988 Eckenhoff
4762791 August 9, 1988 Goeddel et al.
4765989 August 23, 1988 Wong et al.
4783337 November 8, 1988 Wong et al.
4818517 April 4, 1989 Kwee et al.
4820267 April 11, 1989 Harman
4820638 April 11, 1989 Swetly et al.
4826144 May 2, 1989 Balsells
4830344 May 16, 1989 Balsells
4834708 May 30, 1989 Pillari
4840896 June 20, 1989 Reddy et al.
4845196 July 4, 1989 Cowling
4847079 July 11, 1989 Kwan
4851228 July 25, 1989 Zentner et al.
4865845 September 12, 1989 Eckenhoff et al.
4871094 October 3, 1989 Gall et al.
4873080 October 10, 1989 Brickl et al.
4874388 October 17, 1989 Wong et al.
4876781 October 31, 1989 Balsells
4882166 November 21, 1989 Graham et al.
4885166 December 5, 1989 Meyer et al.
4886668 December 12, 1989 Haslam et al.
4892778 January 9, 1990 Theeuwes et al.
4893795 January 16, 1990 Balsells
4897471 January 30, 1990 Stabinsky
4907788 March 13, 1990 Balsells
4915366 April 10, 1990 Balsells
4915949 April 10, 1990 Wong et al.
4915954 April 10, 1990 Ayer et al.
4917887 April 17, 1990 Hauptmann et al.
4917895 April 17, 1990 Lee et al.
4923805 May 8, 1990 Reddy et al.
4927687 May 22, 1990 Nuwayser
4929554 May 29, 1990 Goeddel et al.
4931285 June 5, 1990 Edgren et al.
4934666 June 19, 1990 Balsells
4940465 July 10, 1990 Theeuwes et al.
4940588 July 10, 1990 Sparks et al.
4952402 August 28, 1990 Sparks et al.
4957119 September 18, 1990 de Nijs
4961253 October 9, 1990 Balsells
4964204 October 23, 1990 Balsells
4969884 November 13, 1990 Yum
4974821 December 4, 1990 Balsells
4976966 December 11, 1990 Theeuwes et al.
4994028 February 19, 1991 Leonard et al.
5004689 April 2, 1991 Fiers et al.
5006346 April 9, 1991 Theeuwes et al.
5019382 May 28, 1991 Cummins, Jr.
5019400 May 28, 1991 Gombotz et al.
5023088 June 11, 1991 Wong et al.
5024842 June 18, 1991 Edgren et al.
5030216 July 9, 1991 Theeuwes et al.
5034229 July 23, 1991 Magruder et al.
5053014 October 1, 1991 Van Heugten
5057318 October 15, 1991 Magruder et al.
5059423 October 22, 1991 Magruder et al.
5066436 November 19, 1991 Komen et al.
5071642 December 10, 1991 Lahr et al.
5072070 December 10, 1991 Balsells
5079388 January 7, 1992 Balsells
5090962 February 25, 1992 Landry et al.
5091188 February 25, 1992 Haynes
5108078 April 28, 1992 Balsells
5110596 May 5, 1992 Magruder et al.
5112614 May 12, 1992 Magruder et al.
5113938 May 19, 1992 Clayton
5117066 May 26, 1992 Balsells
D326718 June 2, 1992 Maxwell
5118666 June 2, 1992 Habener
5120306 June 9, 1992 Gosselin
5120712 June 9, 1992 Habener
5120832 June 9, 1992 Goeddel et al.
5122128 June 16, 1992 Cardinal et al.
5122377 June 16, 1992 Miller
5126142 June 30, 1992 Ayer et al.
5126147 June 30, 1992 Silvestri et al.
5134244 July 28, 1992 Balsells
5137727 August 11, 1992 Eckenhoff
D329278 September 8, 1992 Gallup
5147295 September 15, 1992 Stewart
5151093 September 29, 1992 Theeuwes et al.
5160122 November 3, 1992 Balsells
5160743 November 3, 1992 Edgren et al.
5161806 November 10, 1992 Balsells
5180591 January 19, 1993 Margruder et al.
5190765 March 2, 1993 Jao et al.
5192273 March 9, 1993 Bierman
5203849 April 20, 1993 Balsells
5204108 April 20, 1993 Illum
5207752 May 4, 1993 Sorenson et al.
5209746 May 11, 1993 Balaban et al.
5213809 May 25, 1993 Wright et al.
5213810 May 25, 1993 Steber
5219572 June 15, 1993 Sivaramakrishnan
5221278 June 22, 1993 Linkwitz et al.
5223265 June 29, 1993 Wong
5225205 July 6, 1993 Orsolini
5231176 July 27, 1993 Goeddel et al.
5234424 August 10, 1993 Yum et al.
5234692 August 10, 1993 Magruder et al.
5234693 August 10, 1993 Magruder et al.
5234695 August 10, 1993 Hobbs et al.
5250026 October 5, 1993 Ehrlich et al.
5252338 October 12, 1993 Jao et al.
5260069 November 9, 1993 Chen
D342855 January 4, 1994 Butler, II
5276926 January 11, 1994 Lopez
5278151 January 11, 1994 Korb et al.
5279544 January 18, 1994 Gross et al.
5279554 January 18, 1994 Turley
5279555 January 18, 1994 Lifshey
5279608 January 18, 1994 Cherif Cheikh
5284655 February 8, 1994 Bogdansky et al.
5288501 February 22, 1994 Nürnberg et al.
5288502 February 22, 1994 Mcginity et al.
5290271 March 1, 1994 Jemberg
5300079 April 5, 1994 Niezink et al.
5300302 April 5, 1994 Tachon et al.
5308348 May 3, 1994 Balaban et al.
5312335 May 17, 1994 McKinnon et al.
5312389 May 17, 1994 Theeuwes et al.
5312390 May 17, 1994 Wong
5318558 June 7, 1994 Linkwitz et al.
5318780 June 7, 1994 Viegas et al.
5320616 June 14, 1994 Magndu et al.
5324280 June 28, 1994 Wong et al.
5336057 August 9, 1994 Fukuda et al.
5336505 August 9, 1994 Ng et al.
5348544 September 20, 1994 Sweeney et al.
5352662 October 4, 1994 Brooks et al.
5368588 November 29, 1994 Bettinger
5368863 November 29, 1994 Eckenhoff et al.
5371089 December 6, 1994 Rattan
5374620 December 20, 1994 Clark et al.
5385738 January 31, 1995 Yamahira et al.
5385887 January 31, 1995 Yim et al.
5395319 March 7, 1995 Hirsch et al.
5407609 April 18, 1995 Tice et al.
D358644 May 23, 1995 Park
5411951 May 2, 1995 Mitchell
5413572 May 9, 1995 Wong
5413672 May 9, 1995 Hirotsuji et al.
5424286 June 13, 1995 Eng
5428024 June 27, 1995 Chu et al.
5429602 July 4, 1995 Hauser
5439688 August 8, 1995 Orsolini et al.
5443459 August 22, 1995 Wong et al.
5445829 August 29, 1995 Paradissis et al.
5456679 October 10, 1995 Balaban et al.
5458888 October 17, 1995 Chen
5464929 November 7, 1995 Bezwada et al.
5472708 December 5, 1995 Chen
5473564 December 5, 1995 Wantier et al.
5484403 January 16, 1996 Yoakum et al.
5486365 January 23, 1996 Takado et al.
5498255 March 12, 1996 Wong et al.
5511355 April 30, 1996 Dingler
5512293 April 30, 1996 Landrau et al.
5512549 April 30, 1996 Chen et al.
5514110 May 7, 1996 Teh
5529914 June 25, 1996 Hubbell et al.
5531736 July 2, 1996 Wong et al.
5540665 July 30, 1996 Mercado et al.
5540912 July 30, 1996 Roorda et al.
5541172 July 30, 1996 Labrie et al.
5542682 August 6, 1996 Goldstein et al.
5543156 August 6, 1996 Roorda et al.
5545618 August 13, 1996 Buckley et al.
5556642 September 17, 1996 Kobayashi et al.
5557318 September 17, 1996 Gabriel
5558637 September 24, 1996 Allonen et al.
5569289 October 29, 1996 Yoon
5571525 November 5, 1996 Roorda et al.
5574008 November 12, 1996 Johnson et al.
5574137 November 12, 1996 Gray et al.
5580578 December 3, 1996 Oshlack et al.
5589167 December 31, 1996 Cleland et al.
5595751 January 21, 1997 Bezwada
5595759 January 21, 1997 Wright et al.
5597579 January 28, 1997 Bezwada et al.
5602010 February 11, 1997 Hauptmann et al.
5605688 February 25, 1997 Himmler et al.
5607687 March 4, 1997 Bezwada et al.
5609885 March 11, 1997 Rivera et al.
5613954 March 25, 1997 Nelson et al.
5614221 March 25, 1997 Fjellstrom
5614492 March 25, 1997 Habener
5618552 April 8, 1997 Bezwada et al.
5620698 April 15, 1997 Bezwada et al.
5620705 April 15, 1997 Dong et al.
5630796 May 20, 1997 Bellhouse et al.
5633011 May 27, 1997 Dong et al.
5635213 June 3, 1997 Nystrom et al.
5639477 June 17, 1997 Maruyama et al.
5639640 June 17, 1997 Reddy et al.
5645850 July 8, 1997 Bezwada et al.
5648088 July 15, 1997 Bezwada et al.
5650173 July 22, 1997 Ramstack et al.
5654008 August 5, 1997 Herbert et al.
5654010 August 5, 1997 Johnson et al.
5656297 August 12, 1997 Bernstein et al.
5656299 August 12, 1997 Kino et al.
5658593 August 19, 1997 Orly et al.
5660847 August 26, 1997 Magruder et al.
5660858 August 26, 1997 Parikh et al.
5660861 August 26, 1997 Jao et al.
5667803 September 16, 1997 Johnson et al.
5668170 September 16, 1997 Gyory
5672549 September 30, 1997 Minami et al.
5676942 October 14, 1997 Testa et al.
5686097 November 11, 1997 Taskovich et al.
5688801 November 18, 1997 Mesens et al.
5690925 November 25, 1997 Gray et al.
5690952 November 25, 1997 Magruder et al.
5695463 December 9, 1997 Cherif-Cheikh
5697113 December 16, 1997 Shatz
5697914 December 16, 1997 Brimhall
5698213 December 16, 1997 Jamiolkowski et al.
5700486 December 23, 1997 Canal et al.
5700583 December 23, 1997 Jamiolkowski et al.
5703200 December 30, 1997 Bezwada et al.
5707644 January 13, 1998 Illum
5711967 January 27, 1998 Juch
5713847 February 3, 1998 Howard, III et al.
5718922 February 17, 1998 Herrero-Vanrell
5725497 March 10, 1998 Woodruff et al.
5728088 March 17, 1998 Margruder et al.
5728396 March 17, 1998 Peery et al.
5733572 March 31, 1998 Unger et al.
5736159 April 7, 1998 Chen et al.
5738845 April 14, 1998 Imakawa
5747058 May 5, 1998 Tipton et al.
5756450 May 26, 1998 Lorenz et al.
5767251 June 16, 1998 Reddy et al.
5770231 June 23, 1998 Mesens et al.
5782396 July 21, 1998 Mastri et al.
5792477 August 11, 1998 Rickey et al.
5795591 August 18, 1998 Lee et al.
5795779 August 18, 1998 McCormick et al.
5807876 September 15, 1998 Armistead et al.
5810769 September 22, 1998 Schlegel et al.
5814323 September 29, 1998 Lyle
D399821 October 20, 1998 Tyneski
5817129 October 6, 1998 Labrecque et al.
5827297 October 27, 1998 Boudjema
5830501 November 3, 1998 Dong et al.
5836935 November 17, 1998 Ashton et al.
5843891 December 1, 1998 Sherman
5844017 December 1, 1998 Jamiolkowslci et al.
5851451 December 22, 1998 Takechi et al.
5858746 January 12, 1999 Hubbell et al.
5859150 January 12, 1999 Jamiolkowski et al.
5861166 January 19, 1999 Eckenhoff
5871770 February 16, 1999 Margruder et al.
5871778 February 16, 1999 Kino et al.
5874388 February 23, 1999 Hsu
5876746 March 2, 1999 Jona et al.
5882676 March 16, 1999 Lee et al.
D408917 April 27, 1999 Hacker
5904935 May 18, 1999 Eckenhoff et al.
5906599 May 25, 1999 Kaldany
5906816 May 25, 1999 Soos et al.
5906830 May 25, 1999 Farinas et al.
5908621 June 1, 1999 Glue et al.
5916598 June 29, 1999 Rickey et al.
5922253 July 13, 1999 Herbert et al.
5928666 July 27, 1999 Farinas et al.
5932547 August 3, 1999 Stevenson et al.
5938654 August 17, 1999 Wong et al.
5939286 August 17, 1999 Johnson et al.
5942223 August 24, 1999 Bazer et al.
5942253 August 24, 1999 Gombotz et al.
5945126 August 31, 1999 Thanoo et al.
5948430 September 7, 1999 Zerbe et al.
5951521 September 14, 1999 Mastrototaro et al.
5958909 September 28, 1999 Habener
D415073 October 12, 1999 Meehan
5962023 October 5, 1999 Jamiolkowski et al.
5965168 October 12, 1999 Mesens et al.
5972370 October 26, 1999 Eckenhoff et al.
5972373 October 26, 1999 Yajima et al.
5976109 November 2, 1999 Heruth
5980945 November 9, 1999 Ruiz
5981719 November 9, 1999 Woiszwillo et al.
5984890 November 16, 1999 Gast et al.
5985305 November 16, 1999 Peery et al.
5989463 November 23, 1999 Tracy et al.
5997527 December 7, 1999 Gumucio et al.
5997902 December 7, 1999 Maruyama et al.
6007805 December 28, 1999 Foster et al.
6017545 January 25, 2000 Modi
6022561 February 8, 2000 Carlsson et al.
6023802 February 15, 2000 King
6029361 February 29, 2000 Newman
6053927 April 25, 2000 Hamas
6056718 May 2, 2000 Funderburk et al.
6060450 May 9, 2000 Soos et al.
6069133 May 30, 2000 Carlo et al.
6074377 June 13, 2000 Sanfilippo, II
6074660 June 13, 2000 Jamiolkowski et al.
6074673 June 13, 2000 Guillen
6100346 August 8, 2000 Jamiolkowski et al.
6110503 August 29, 2000 Rickey et al.
D430671 September 5, 2000 Shute
6113938 September 5, 2000 Chen et al.
6113947 September 5, 2000 Cleland et al.
6120787 September 19, 2000 Gustafsson et al.
6124261 September 26, 2000 Stevenson et al.
6124281 September 26, 2000 Lewis et al.
6127520 October 3, 2000 Ueda et al.
6129761 October 10, 2000 Hubbell
6130200 October 10, 2000 Brodbeck et al.
6132420 October 17, 2000 Dionne et al.
6133249 October 17, 2000 Hills
6133429 October 17, 2000 Davis et al.
6146139 November 14, 2000 Harrison, III
6147168 November 14, 2000 Jamiolkowski et al.
6156331 December 5, 2000 Peery et al.
6172046 January 9, 2001 Albrecht
6174547 January 16, 2001 Dong et al.
6177096 January 23, 2001 Zerbe et al.
6183461 February 6, 2001 Matsuura et al.
6187095 February 13, 2001 Labrecque et al.
6190350 February 20, 2001 Davis et al.
6190700 February 20, 2001 Okada et al.
6190702 February 20, 2001 Takada et al.
6191102 February 20, 2001 DiMarchi et al.
6204022 March 20, 2001 Johnson et al.
6217393 April 17, 2001 Pellet et al.
6217906 April 17, 2001 Gumucio et al.
6217908 April 17, 2001 Mathiowitz et al.
6218431 April 17, 2001 Schoen et al.
6224894 May 1, 2001 Jamiolkowski et al.
6235712 May 22, 2001 Stevenson et al.
6245349 June 12, 2001 Yiv et al.
6245357 June 12, 2001 Edgren et al.
6248112 June 19, 2001 Gambale et al.
6251435 June 26, 2001 Jamiolkowski et al.
D445975 July 31, 2001 Stratford
6258377 July 10, 2001 New et al.
6261584 July 17, 2001 Peery et al.
6268343 July 31, 2001 Knudsen et al.
6270700 August 7, 2001 Ignatious
6270787 August 7, 2001 Ayer
6277413 August 21, 2001 Sankaram
6283949 September 4, 2001 Roorda
6284264 September 4, 2001 Zerbe et al.
6284727 September 4, 2001 Kim et al.
6287295 September 11, 2001 Chen et al.
6284725 September 4, 2001 Coolidge et al.
6329336 December 11, 2001 Bridon et al.
6331311 December 18, 2001 Brodbeck et al.
6372218 April 16, 2002 Cummins, Jr.
6372256 April 16, 2002 Jamiolkowski et al.
6375978 April 23, 2002 Kleiner et al.
D456776 May 7, 2002 Lindekugel
6395282 May 28, 2002 Kende et al.
6395292 May 28, 2002 Peery et al.
6402716 June 11, 2002 Ryoo et al.
6403655 June 11, 2002 Bezwada et al.
6419952 July 16, 2002 Wong et al.
6428517 August 6, 2002 Hochman et al.
6433144 August 13, 2002 Morris et al.
6436091 August 20, 2002 Harper et al.
6447522 September 10, 2002 Gambale et al.
6451974 September 17, 2002 Hansen
6458385 October 1, 2002 Jamiolkowski et al.
6458387 October 1, 2002 Scott et al.
6458924 October 1, 2002 Knudsen et al.
6461605 October 8, 2002 Cutler et al.
6464688 October 15, 2002 Harper et al.
6468961 October 22, 2002 Brodbeck et al.
6471688 October 29, 2002 Harper et al.
6472512 October 29, 2002 LaFleur et al.
6478768 November 12, 2002 Kneer
6485706 November 26, 2002 McCoy et al.
6495164 December 17, 2002 Ramstack et al.
6506724 January 14, 2003 Hiles et al.
6508808 January 21, 2003 Carr et al.
6514500 February 4, 2003 Bridon et al.
6514517 February 4, 2003 Jamilolkowski et al.
6524305 February 25, 2003 Peterson et al.
6528093 March 4, 2003 Kamei et al.
6528486 March 4, 2003 Larsen et al.
D472896 April 8, 2003 Peiker
6541021 April 1, 2003 Johnson et al.
6544239 April 8, 2003 Kinsey et al.
6544252 April 8, 2003 Theeuwes et al.
6547250 April 15, 2003 Noble
6551613 April 22, 2003 Dong et al.
6569420 May 27, 2003 Chen et al.
6572890 June 3, 2003 Faour et al.
6579851 June 17, 2003 Goeke et al.
6589157 July 8, 2003 Fontayne et al.
6592508 July 15, 2003 Ravins et al.
6592887 July 15, 2003 Zerbe et al.
6593295 July 15, 2003 Bridon et al.
6607529 August 19, 2003 Jones et al.
6626863 September 30, 2003 Berler
6635268 October 21, 2003 Peery et al.
6645192 November 11, 2003 Kenison et al.
6667061 December 23, 2003 Rarnstack et al.
6670368 December 30, 2003 Breault et al.
6673767 January 6, 2004 Brodbeck et al.
6682522 January 27, 2004 Carr et al.
6703225 March 9, 2004 Kojima et al.
6703359 March 9, 2004 Young et al.
6706689 March 16, 2004 Coolidge et al.
6709671 March 23, 2004 Zerbe et al.
6720407 April 13, 2004 Hughes et al.
6730328 May 4, 2004 Maskiwicz et al.
6767887 July 27, 2004 Hoffmann et al.
6821949 November 23, 2004 Bridon et al.
6833256 December 21, 2004 Pontzer et al.
6835194 December 28, 2004 Johnson et al.
6840931 January 11, 2005 Peterson et al.
6849708 February 1, 2005 Habener
6849714 February 1, 2005 Bridon et al.
6858576 February 22, 2005 Young et al.
6872700 March 29, 2005 Young et al.
6875748 April 5, 2005 Manthorpe et al.
6887470 May 3, 2005 Bridon et al.
6887849 May 3, 2005 Bridon et al.
6899887 May 31, 2005 Ayer
6899898 May 31, 2005 Albayrak
6902744 June 7, 2005 Kolterman et al.
6903186 June 7, 2005 Dong
6913767 July 5, 2005 Cleland et al.
6923800 August 2, 2005 Chen et al.
6924264 August 2, 2005 Prickett et al.
6939556 September 6, 2005 Lautenbach
6956026 October 18, 2005 Beeley et al.
6960192 November 1, 2005 Flaherty et al.
6969702 November 29, 2005 Bertilsson et al.
6976981 December 20, 2005 Ayer
6989366 January 24, 2006 Beeley et al.
6992065 January 31, 2006 Okumu
6997922 February 14, 2006 Theeuwes et al.
7008439 March 7, 2006 Janzen et al.
7014636 March 21, 2006 Gilbert
7022674 April 4, 2006 DeFelippis et al.
7041646 May 9, 2006 Pan et al.
7074423 July 11, 2006 Fereira et al.
7084243 August 1, 2006 Glaesner et al.
7101567 September 5, 2006 Sano et al.
7101843 September 5, 2006 Glaesner et al.
7112335 September 26, 2006 Lautenbach
7115569 October 3, 2006 Beeley et al.
7138375 November 21, 2006 Beeley et al.
7138486 November 21, 2006 Habener et al.
7141547 November 28, 2006 Rosen et al.
7144863 December 5, 2006 DeFelippis et al.
7153825 December 26, 2006 Young
7157555 January 2, 2007 Beeley et al.
7163688 January 16, 2007 Peery et al.
7163697 January 16, 2007 Hanes et al.
7199217 April 3, 2007 DiMarchi et al.
7205409 April 17, 2007 Pei et al.
7207982 April 24, 2007 Dionne et al.
7214206 May 8, 2007 Rue et al.
7241457 July 10, 2007 Chen et al.
7258869 August 21, 2007 Berry et al.
D555589 November 20, 2007 Hussaini
7297761 November 20, 2007 Beeley et al.
7316680 January 8, 2008 Gilbert
7393827 July 1, 2008 Nadler
7407499 August 5, 2008 Trautman
7442682 October 28, 2008 Kitaura et al.
7456254 November 25, 2008 Wright et al.
7459432 December 2, 2008 Cowley et al.
7521423 April 21, 2009 Young et al.
7563871 July 21, 2009 Wright et al.
7589169 September 15, 2009 Bolotin
7604647 October 20, 2009 Chen
7612176 November 3, 2009 Wright et al.
7632256 December 15, 2009 Mosler et al.
7635463 December 22, 2009 Bolotin et al.
D608447 January 19, 2010 Meyer
7655254 February 2, 2010 Dennis et al.
7655257 February 2, 2010 Peery et al.
7666835 February 23, 2010 Bloom et al.
7682356 March 23, 2010 Alessi et al.
7727519 June 1, 2010 Moran
7731947 June 8, 2010 Eliaz et al.
7736665 June 15, 2010 Patel et al.
7741269 June 22, 2010 Young et al.
7766924 August 3, 2010 Bombard et al.
7790140 September 7, 2010 Bolotin
7825091 November 2, 2010 Bloom et al.
7829109 November 9, 2010 Chen et al.
7833543 November 16, 2010 Gibson et al.
7879028 February 1, 2011 Alessi et al.
7879794 February 1, 2011 Berry et al.
7919109 April 5, 2011 Berry et al.
D638478 May 24, 2011 Block
7928065 April 19, 2011 Rohloff et al.
7964183 June 21, 2011 Eliaz et al.
8039432 October 18, 2011 Bridon et al.
7959938 June 14, 2011 Lautenbach et al.
8048438 November 1, 2011 Berry et al.
8052996 November 8, 2011 Lautenbach et al.
8058233 November 15, 2011 Cowley et al.
8101576 January 24, 2012 Bloom
8114430 February 14, 2012 Rohloff et al.
8114437 February 14, 2012 Rohloff et al.
8158150 April 17, 2012 Lautenbach et al.
8173150 May 8, 2012 Berry et al.
8202836 June 19, 2012 Moore et al.
8206745 June 26, 2012 Rohloff et al.
8211467 July 3, 2012 Rohloff et al.
8217001 July 10, 2012 Cowley et al.
8231859 July 31, 2012 Bolotin et al.
8251946 August 28, 2012 Bardy
8257682 September 4, 2012 Bolotin et al.
8257691 September 4, 2012 Eliaz et al.
8262667 September 11, 2012 Silver et al.
8263545 September 11, 2012 Bloom
8263736 September 11, 2012 Berry
8268341 September 18, 2012 Berry
8273365 September 25, 2012 Lautenbach et al.
8273713 September 25, 2012 Pittner et al.
D669589 October 23, 2012 Delaey
8277776 October 2, 2012 Boictin et al.
8278267 October 2, 2012 Weyer et al.
8288338 October 16, 2012 Alessi et al.
8298561 October 30, 2012 Alessi et al.
8299025 October 30, 2012 Alessi et al.
8343140 January 1, 2013 Alessi et al.
8367095 February 5, 2013 Lautenbach et al.
8372424 February 12, 2013 Berry et al.
D678889 March 26, 2013 Chiu
8398967 March 19, 2013 Eliaz et al.
8440226 May 14, 2013 Rohloff et al.
8454552 June 4, 2013 Bardy
8460694 June 11, 2013 Rohloff et al.
8470353 June 25, 2013 Lautenbach et al.
8556861 October 15, 2013 Tsals
8722037 May 13, 2014 Veenstra et al.
8747412 June 10, 2014 Bae et al.
8801700 August 12, 2014 Alessi et al.
8815802 August 26, 2014 Kalthoff et al.
8845726 September 30, 2014 Tebbe
8858621 October 14, 2014 Oba
8865202 October 21, 2014 Zerbe et al.
8888745 November 18, 2014 Van Der Graaf et al.
8926595 January 6, 2015 Alessi et al.
8940316 January 27, 2015 Alessi et al.
8992961 March 31, 2015 Berry et al.
8992962 March 31, 2015 Lautenbach et al.
9044209 June 2, 2015 Dayton et al.
9078900 July 14, 2015 Kuzma et al.
9095553 August 4, 2015 Rohloff et al.
9241722 January 26, 2016 Yu
D750764 March 1, 2016 DeSocio
9332995 May 10, 2016 Russo
9526763 December 27, 2016 Rohloff et al.
9539200 January 10, 2017 Lautenbach
9572889 February 21, 2017 Alessi et al.
D789539 June 13, 2017 Kleiner
D789540 June 13, 2017 Gyorgy
9682127 June 20, 2017 Alessi et al.
RE46577 October 24, 2017 Collins
D805199 December 12, 2017 Chen
D810289 February 13, 2018 Jutila
9889085 February 13, 2018 Alessi et al.
9931133 April 3, 2018 Mirza
D816843 May 1, 2018 Lewis
D819820 June 5, 2018 Radau
20010012511 August 9, 2001 Bezwada et al.
20010021377 September 13, 2001 Jamiolkowski et al.
20010021822 September 13, 2001 Ayer
20010022974 September 20, 2001 Ayer
20010026793 October 4, 2001 Jamiolkowski et al.
20010027311 October 4, 2001 Chen et al.
20010031940 October 18, 2001 Loos
20010031790 October 18, 2001 Beisswenger
20010036472 November 1, 2001 Wong et al.
20010040326 November 15, 2001 Balczun
20020001631 January 3, 2002 Okumu
20020004481 January 10, 2002 Cleland et al.
20020012818 January 31, 2002 Ruppi et al.
20020034532 March 21, 2002 Brodbeck et al.
20020037309 March 28, 2002 Jaworowicz et al.
20020048600 April 25, 2002 Bhatt et al.
20020077599 June 20, 2002 Wojcik
20020098180 July 25, 2002 Lei
20020136848 September 26, 2002 Yoshii et al.
20020137666 September 26, 2002 Beeley et al.
20020141985 October 3, 2002 Pittner et al.
20020197185 December 26, 2002 Jamiolkowski et al.
20020197235 December 26, 2002 Moran
20030007992 January 9, 2003 Gibson et al.
20030032947 February 13, 2003 Harper et al.
20030040699 February 27, 2003 Talling
20030044467 March 6, 2003 Brodbeck et al.
20030045454 March 6, 2003 Okumu et al.
20030059376 March 27, 2003 Libbey et al.
20030059471 March 27, 2003 Compton et al.
20030060425 March 27, 2003 Ahlem et al.
20030078618 April 24, 2003 Fey et al.
20030097121 May 22, 2003 Babcock et al.
20030104063 June 5, 2003 Babcock et al.
20030108608 June 12, 2003 Berry et al.
20030108609 June 12, 2003 Berry et al.
20030113380 June 19, 2003 Ramstack et al.
20030114837 June 19, 2003 Peterson et al.
20030118660 June 26, 2003 Rickey et al.
20030135153 July 17, 2003 Hagemeier
20030138403 July 24, 2003 Drustrup
20030138491 July 24, 2003 Tracy et al.
20030157178 August 21, 2003 Chen et al.
20030170289 September 11, 2003 Chen et al.
20030180364 September 25, 2003 Chen et al.
20030186858 October 2, 2003 Arentsen
20030191099 October 9, 2003 Bohlmann et al.
20030211974 November 13, 2003 Brodbeck et al.
20030215515 November 20, 2003 Truong-Le et al.
20030220617 November 27, 2003 Dickerson
20030233101 December 18, 2003 Lubock et al.
20040001689 January 1, 2004 Goldsmith et al.
20040001889 January 1, 2004 Chen et al.
20040002442 January 1, 2004 Pan et al.
20040022859 February 5, 2004 Chen et al.
20040024068 February 5, 2004 Chen et al.
20040024069 February 5, 2004 Chen et al.
20040029784 February 12, 2004 Hathaway
20040039376 February 26, 2004 Peery et al.
20040047888 March 11, 2004 Kenison et al.
20040097906 May 20, 2004 Fereira et al.
20040101557 May 27, 2004 Gibson et al.
20040102762 May 27, 2004 Gilbert
20040115236 June 17, 2004 Chan et al.
20040142867 July 22, 2004 Oi et al.
20040142902 July 22, 2004 Stmijker-Boudier
20040151753 August 5, 2004 Chen et al.
20040157951 August 12, 2004 Wolf
20040198654 October 7, 2004 Glaesner et al.
20040199140 October 7, 2004 Rue
20040209801 October 21, 2004 Brand et al.
20040215133 October 28, 2004 Weber et al.
20040224903 November 11, 2004 Berry et al.
20040225113 November 11, 2004 LaFleur et al.
20040243106 December 2, 2004 Ayer
20040265273 December 30, 2004 Li et al.
20040266683 December 30, 2004 Hathaway et al.
20040266692 December 30, 2004 Young et al.
20050004557 January 6, 2005 Russell
20050008661 January 13, 2005 Fereira et al.
20050009742 January 13, 2005 Bertilsson et al.
20050010196 January 13, 2005 Fereira et al.
20050070883 March 31, 2005 Brown et al.
20050070927 March 31, 2005 Feinberg
20050079200 April 14, 2005 Rathenow et al.
20050079202 April 14, 2005 Chen et al.
20050010942 January 13, 2005 Eliaz et al.
20050095284 May 5, 2005 Trautman
20050101943 May 12, 2005 Ayer et al.
20050106214 May 19, 2005 Chen
20050112188 May 26, 2005 Eliaz et al.
20050118206 June 2, 2005 Luk et al.
20050118221 June 2, 2005 Blakely et al.
20050131386 June 16, 2005 Freeman et al.
20050131389 June 16, 2005 Peterson et al.
20050143749 June 30, 2005 Zalenski et al.
20050175701 August 11, 2005 Pan et al.
20050201980 September 15, 2005 Moran
20050215475 September 29, 2005 Ong et al.
20050216087 September 29, 2005 Zucherman et al.
20050266087 December 1, 2005 Junnarkar et al.
20050271702 December 8, 2005 Wright et al.
20050276856 December 15, 2005 Fereira et al.
20050281879 December 22, 2005 Chen et al.
20060013879 January 19, 2006 Brodbeck et al.
20060014678 January 19, 2006 Cowley et al.
20060030526 February 9, 2006 Liu et al.
20060069029 March 30, 2006 Kolterman et al.
20060073182 April 6, 2006 Wong et al.
20060084604 April 20, 2006 Kitaura et al.
20060084922 April 20, 2006 Botha
20060094652 May 4, 2006 Levy et al.
20060094693 May 4, 2006 Aziz et al.
20060106399 May 18, 2006 Taras et al.
20060141040 June 29, 2006 Chen et al.
20060142234 June 29, 2006 Chen et al.
20060160736 July 20, 2006 Nadler
20060178304 August 10, 2006 Juul-Mortensen et al.
20060193918 August 31, 2006 Rohloff et al.
20060216242 September 28, 2006 Rohloff et al.
20060224145 October 5, 2006 Gills
20060233841 October 19, 2006 Brodbeck et al.
20060246138 November 2, 2006 Rohloff et al.
20060251618 November 9, 2006 Dennis et al.
20060263433 November 23, 2006 Ayer et al.
20060264890 November 23, 2006 Moberg et al.
20060280795 December 14, 2006 Penhasi et al.
20060293232 December 28, 2006 Levy et al.
20070027105 February 1, 2007 Junnarkar et al.
20070141102 June 21, 2007 De Graaff et al.
20070149011 June 28, 2007 Kent et al.
20070166352 July 19, 2007 Wright et al.
20070207958 September 6, 2007 Bridon et al.
20070248572 October 25, 2007 Moran et al.
20070281024 December 6, 2007 Lautenbach et al.
20080020016 January 24, 2008 Li et al.
20080038316 February 14, 2008 Wong et al.
20080064636 March 13, 2008 Bloom et al.
20080065090 March 13, 2008 Scribner et al.
20080091176 April 17, 2008 Alessi et al.
20080110515 May 15, 2008 Angelosanto et al.
20080112994 May 15, 2008 Junnarkar et al.
20080200383 August 21, 2008 Jennings et al.
20080207512 August 28, 2008 Roth et al.
20080208194 August 28, 2008 Bickenbach
20080226625 September 18, 2008 Berry et al.
20080226689 September 18, 2008 Berry et al.
20080260838 October 23, 2008 Hokenson et al.
20080260840 October 23, 2008 Alessi et al.
20080269725 October 30, 2008 Deem et al.
20080312157 December 18, 2008 Levy et al.
20090012463 January 8, 2009 Beelen et al.
20090022727 January 22, 2009 Houston et al.
20090036364 February 5, 2009 Levy et al.
20090042781 February 12, 2009 Petersen et al.
20090074734 March 19, 2009 Rottiers
20090087408 April 2, 2009 Berry et al.
20090125030 May 14, 2009 Tebbe
20090156474 June 18, 2009 Roth et al.
20090163447 June 25, 2009 Maggio
20090186817 July 23, 2009 Ghosh et al.
20090202481 August 13, 2009 Li et al.
20090202608 August 13, 2009 Alessi et al.
20090209460 August 20, 2009 Young et al.
20090210019 August 20, 2009 Kim et al.
20090215694 August 27, 2009 Kolterman et al.
20090234392 September 17, 2009 Dziedzic
20090247463 October 1, 2009 Wright et al.
20090254143 October 8, 2009 Tweden et al.
20090286723 November 19, 2009 Levy et al.
20090312246 December 17, 2009 Baron et al.
20100092566 April 15, 2010 Alessi et al.
20100094252 April 15, 2010 Wengreen et al.
20100105627 April 29, 2010 Salama et al.
20100144621 June 10, 2010 Kim et al.
20100185184 July 22, 2010 Alessi et al.
20100297209 November 25, 2010 Rohloff et al.
20100298807 November 25, 2010 Jansen et al.
20100298840 November 25, 2010 Schwartz
20100331868 December 30, 2010 Bardy
20110076317 March 31, 2011 Alessi et al.
20110091527 April 21, 2011 Moonen et al.
20110104111 May 5, 2011 Rohloff et al.
20110152181 June 23, 2011 Alsina-Fernandez et al.
20110152182 June 23, 2011 Alsina-Fernandez et al.
20110160708 June 30, 2011 Berry et al.
20110166554 July 7, 2011 Alessi et al.
20110264077 October 27, 2011 Rohloff et al.
20110306549 December 15, 2011 Tatarkiewicz et al.
20120178687 July 12, 2012 Alessi et al.
20120208755 August 16, 2012 Leung
20120265232 October 18, 2012 Surbone
20120303045 November 29, 2012 Cooper et al.
20130030417 January 31, 2013 Alessi
20130034210 February 7, 2013 Rohloff et al.
20130052237 February 28, 2013 Eliaz et al.
20130296661 November 7, 2013 Bornzin et al.
20130324977 December 5, 2013 Vanderpool
20140058409 February 27, 2014 Bratlie
20140058425 February 27, 2014 Porat
20140121741 May 1, 2014 Bennett et al.
20140148837 May 29, 2014 Levitan
20140163057 June 12, 2014 Patel et al.
20140236162 August 21, 2014 Barongan
20140257272 September 11, 2014 Clark, III et al.
20140324067 October 30, 2014 Emken
20140378900 December 25, 2014 Alessi et al.
20150111818 April 23, 2015 Alessi et al.
20150057227 February 26, 2015 Leung
20150133791 May 14, 2015 Sato et al.
20150231062 August 20, 2015 Lautenbach et al.
20150231256 August 20, 2015 Berry et al.
20150297509 October 22, 2015 Schwarz
20150359553 December 17, 2015 Harnisch
20160022582 January 28, 2016 Alessi et al.
20160030337 February 4, 2016 Kuzma et al.
20160354115 December 8, 2016 Smith
20160354305 December 8, 2016 Alessi et al.
20170056476 March 2, 2017 Rohloff et al.
20170079906 March 23, 2017 Alessi et al.
20170119854 May 4, 2017 Alessi et al.
20170119855 May 4, 2017 Berry et al.
20170181964 June 29, 2017 Lautenbach et al.
20170252409 September 7, 2017 Leung
20170273706 September 28, 2017 Mirza
20170319470 November 9, 2017 Eliaz et al.
20170319662 November 9, 2017 Berry et al.
20170348392 December 7, 2017 Rohloff et al.
20170368145 December 28, 2017 Alessi et al.
20180009871 January 11, 2018 Blackwell et al.
20180193059 July 12, 2018 Bae
Foreign Patent Documents
000000635692 September 1936 DE
0079405 May 1983 EP
0254394 January 1988 EP
0295411 December 1988 EP
0304107 February 1989 EP
0368339 May 1990 EP
0373867 June 1990 EP
0431942 June 1991 EP
0486959 May 1992 EP
0497575 August 1992 EP
0521586 January 1993 EP
0596161 May 1994 EP
0379147 September 1994 EP
0627231 December 1994 EP
0631794 January 1995 EP
0729747 May 1997 EP
0771817 May 1997 EP
0596161 February 1998 EP
0841359 May 1998 EP
0767689 June 1999 EP
1046399 October 2000 EP
1084703 March 2001 EP
1300129 April 2003 EP
1300173 April 2003 EP
1300129 May 2003 EP
1323450 July 2003 EP
1600187 January 2009 EP
2133073 December 2009 EP
2020990 September 2010 EP
640907 July 1928 FR
2616665 December 1988 FR
1049104 November 1966 GB
1518683 July 1978 GB
2138298 November 1986 GB
2501400 October 2013 GB
2501400 October 2013 GB
H02124814 May 1990 JP
H07196479 August 1995 JP
1997/509346 September 1997 JP
9241153 September 1997 JP
11-100353 April 1999 JP
2006/213727 August 2006 JP
8901004 November 1990 NL
9000948 November 1990 NL
9100160 August 1992 NL
9100160 August 1992 NL
592113 August 2012 NZ
200634060 October 2006 TW
WO 1989/003678 May 1989 WO
WO-1990/013285 November 1990 WO
WO-1990/013361 November 1990 WO
WO-1990/013780 November 1990 WO
WO 91/07160 May 1991 WO
WO-1992/019241 November 1992 WO
WO 93/06819 April 1993 WO
WO 93/06821 April 1993 WO
WO 93/008832 May 1993 WO
WO 93/09763 May 1993 WO
WO 93/23083 November 1993 WO
WO 94/09743 May 1994 WO
WO-1994/010982 May 1994 WO
WO 94/21262 September 1994 WO
WO 95/01167 January 1995 WO
WO 95/09006 April 1995 WO
WO 95/09007 April 1995 WO
WO 1995/013799 May 1995 WO
WO 95/34285 December 1995 WO
WO 96/001134 January 1996 WO
WO 96/003116 February 1996 WO
WO-1996/036317 November 1996 WO
WO 96/39142 December 1996 WO
WO 96/40049 December 1996 WO
WO 96/40139 December 1996 WO
WO 96/40355 December 1996 WO
WO-1996/040049 December 1996 WO
WO 97/15289 May 1997 WO
WO 97/15296 May 1997 WO
WO 97/28181 August 1997 WO
WO-1997/031943 September 1997 WO
WO-1997/044039 November 1997 WO
WO 97/46204 December 1997 WO
WO 97/47339 December 1997 WO
WO 98/00152 January 1998 WO
WO 98/00157 January 1998 WO
WO 98/00158 January 1998 WO
WO 98/02169 January 1998 WO
WO-1997/041837 February 1998 WO
WO-1998/007412 February 1998 WO
WO 98/13091 April 1998 WO
WO 98/13092 April 1998 WO
WO 98/16250 April 1998 WO
WO 98/17315 April 1998 WO
WO 98/20930 May 1998 WO
WO 98/27960 July 1998 WO
WO 98/027962 July 1998 WO
WO 98/27963 July 1998 WO
WO 98/030231 July 1998 WO
WO 98/32463 July 1998 WO
WO-1998/030231 July 1998 WO
WO 98/42317 October 1998 WO
WO 98/47487 October 1998 WO
WO 98/51282 November 1998 WO
WO 98/58698 December 1998 WO
WO 99/03453 January 1999 WO
WO 99/04767 February 1999 WO
WO 99/004768 February 1999 WO
WO-1999/012549 March 1999 WO
WO 99/16419 April 1999 WO
WO 99/025728 May 1999 WO
WO 99/29306 June 1999 WO
WO 99/033446 July 1999 WO
WO 99/33449 July 1999 WO
WO 99/39700 August 1999 WO
WO 99/040788 August 1999 WO
WO 99/044659 September 1999 WO
WO 99/062501 December 1999 WO
WO 99/064061 December 1999 WO
WO 00/013663 March 2000 WO
WO 00/029206 May 2000 WO
WO 00/038652 July 2000 WO
WO 00/039280 July 2000 WO
WO 00/040273 July 2000 WO
WO 00/041548 July 2000 WO
WO 00/045790 August 2000 WO
WO 00/054745 September 2000 WO
WO-2000/059476 October 2000 WO
WO 00/066138 November 2000 WO
WO 00/067728 November 2000 WO
WO-2000/066087 November 2000 WO
WO-2001/019345 March 2001 WO
WO 01/28631 April 2001 WO
WO-2001/028525 April 2001 WO
WO 01/043528 June 2001 WO
WO 01/051041 July 2001 WO
WO 01/68168 September 2001 WO
WO 01/78683 October 2001 WO
WO 02/028366 April 2002 WO
WO 02/036072 May 2002 WO
WO 02/043800 June 2002 WO
WO 02/045752 June 2002 WO
WO 02/47716 June 2002 WO
WO 02/067895 September 2002 WO
WO 02/069983 September 2002 WO
WO 02/76344 October 2002 WO
WO 02/085428 October 2002 WO
WO 03/000230 January 2003 WO
WO 03/007981 January 2003 WO
WO 03/011892 February 2003 WO
WO 03/024357 March 2003 WO
WO 03/024503 March 2003 WO
WO-2003/020245 March 2003 WO
WO 03/030923 April 2003 WO
WO 03/041684 May 2003 WO
WO 03/041757 May 2003 WO
WO 03/053400 July 2003 WO
WO-2003/066585 August 2003 WO
WO 03/072113 September 2003 WO
WO 03/072133 September 2003 WO
WO 04/002565 January 2004 WO
WO 2004/026106 April 2004 WO
WO-2004/034975 April 2004 WO
WO-2004/035754 April 2004 WO
WO-2004/035762 April 2004 WO
WO 2004/036186 April 2004 WO
WO 04/046338 June 2004 WO
WO 04/052336 June 2004 WO
WO 04/056338 July 2004 WO
WO 04/089335 October 2004 WO
WO 2004/089458 October 2004 WO
WO-2004/103342 December 2004 WO
WO 05/048930 June 2005 WO
WO 05/048952 June 2005 WO
WO 05/102293 November 2005 WO
WO 2005/102293 November 2005 WO
WO-2005/110425 November 2005 WO
WO 06/017772 February 2006 WO
WO 06/023526 March 2006 WO
WO 2006/077242 July 2006 WO
WO 2006/077250 July 2006 WO
WO 06/081279 August 2006 WO
WO 06/083761 August 2006 WO
WO 06/084139 August 2006 WO
WO 06/086727 August 2006 WO
WO 06/101815 September 2006 WO
WO 06/111169 October 2006 WO
WO-2006/131730 December 2006 WO
WO 07/024700 March 2007 WO
WO 07/056681 May 2007 WO
WO 07/075534 July 2007 WO
WO 07/084460 July 2007 WO
WO 2007/082889 July 2007 WO
WO 07/133778 November 2007 WO
WO 07/140416 December 2007 WO
WO 08/021133 February 2008 WO
WO-2008/041245 April 2008 WO
WO 08/061355 May 2008 WO
WO-2008/086086 July 2008 WO
WO 08/133908 November 2008 WO
WO 08/134425 November 2008 WO
WO 09/109927 September 2009 WO
WO-2009/143285 November 2009 WO
WO 2010/045169 April 2010 WO
WO 2013/004983 January 2013 WO
WO 2013/184235 December 2013 WO
Other references
  • Croxatto. “Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant.” Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8.
  • Implanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
  • Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
  • Probuphine_Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016.
  • International Search Report and Written Opinion for PCT Application No. PCT/US2016/035602 dated Nov. 29, 2016.
  • Adolf, “Human interferon omega-a review,” Mult. Sclr. 1:S44-47 (1995).
  • Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002).
  • Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010).
  • Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
  • Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998).
  • Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994).
  • Lublin et al., “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology. 46:907-911 (1996).
  • Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
  • Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005).
  • Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study,” Acta. Neurol. Scand. 100:283-289 (1999).
  • Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis,” Neurology 43:662-667 (1993).
  • PCT International Search Report for PCT/US2009/000916, 4 pages (dated Aug. 12, 2009).
  • “Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1,” NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release).
  • Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011).
  • Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010).
  • Roberts et al., “The Evolution of the Type I Interferonsl,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998).
  • Rohloff et al., “DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
  • “Sequence Listings for International Patent Application Publication No. WO2009109927, WIPO Patentscope”, http://patentscope.wipoint/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012).
  • Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004).
  • Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
  • Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011).
  • Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997).
  • Pratley et al., “Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors,” Rev. Diabet. Stud., 5(2):73-94 (2008).
  • Gonzalez, et al., “Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico,” Salud Publica Mex 55:462-468 (2013).
  • Ahn et al., “A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning” Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116.
  • “Abstracts 2007,” Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (XP002538652).
  • Jetschmann et al., “Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C,” Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454).
  • Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
  • “Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209211 (Dec. 1994).
  • “Search Report and Written Opinion” dated Dec. 19, 2008 for PCT/US2008/005235, filed Apr. 22, 2008.
  • Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997).
  • Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990).
  • Adolf et al., “Antigenic structure of human interferon ω1 (Interferon αll 1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987).
  • Adolf et al., “Purification and characterization of natural human interferon ωl,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
  • Adolf et al., “Human interferon ωl: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991).
  • Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
  • ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984).
  • Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
  • Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
  • Aulitzky, “ Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama,” Journal of Clinical Oncology 7(12):1875-1884 (1989).
  • Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972).
  • Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C,” Bioconjugate Chemistry 12(2):195-202 (2001).
  • Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996).
  • Bakhtiar et al, “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
  • Balkwill,F., “Interferons,” Lancet 1(8646):1060-1063 (May 1989).
  • Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
  • Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419-423 (Feb. 2001).
  • Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983).
  • Bell et al, “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201209 (1995).
  • Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995).
  • Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994).
  • Bolinger et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992).
  • Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
  • Borden et al., “Second-generation interferons for cancer: clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
  • Boué et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000).
  • Buckwold et. al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
  • Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996).
  • CAS Number: 56-81-5 (Nov. 16, 1984).
  • Chang et al., “Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996).
  • Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967).
  • Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
  • Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983).
  • Condino-Neto, “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000).
  • Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
  • Das et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm, 2(11):44-51 (1999).
  • Dash et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998).
  • Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570).
  • Deacon et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
  • Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994).
  • Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
  • Dorr et al., “Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988).
  • Uhlig et al., “The electro-osmotic actuation of implantable insulin micropumps,” J. Biomed. Materials Res. 17:931-943 (1983).
  • Efendic et al., “Overview of incretin hormones,” Honn. Metab. Res., 36(11-12):742-746 (2004).
  • Eissele et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994).
  • Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000).
  • Eng et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992).
  • Eng et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990).
  • Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985).
  • Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993).
  • Fang et al., “The impact of baseline liver histology on virologic response to interferon α-2b±ρ ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
  • Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993).
  • Ferenci et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977).
  • Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon β,” Lancet 356(9223):41 (Jul. 2000).
  • Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase,” J. Medicinal Chem. 38(19):3829-3837 (1995).
  • Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001).
  • Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP),” Int'l J. Pharmaceutics 234(1-2):121-128 (2002).
  • Luft et al., “Electro-osmotic valve for the controlled administration of drugs,” Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract).
  • Gan To Kagaku Ryoho, “Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract).
  • Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneurnologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
  • Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer,” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
  • Ghiglione et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia 27:599-600 (1984).
  • Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
  • Goke et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993).
  • Gonzales et al., “Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975).
  • Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon alpha,” Cancer Chemother. Pharrnacol. 37(1-2):39-46 (1995).
  • Grant et al., “Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439-442 (Aug. 2000).
  • Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992).
  • Hageman, “The Role of Moisture in Protein Stability, ” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988).
  • Heathcote et al., “Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23) 1673-1680 (2000).
  • Heim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
  • Heinrich et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984).
  • Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998).
  • Hellstrand et al., “Histamine and the response to IFN-α in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
  • Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
  • Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993).
  • Hodoshima et al., “Lipid nanoparticles for delivering antitumor drugs,” International Journal of Pharmaceutics, 146(1):81-92 (1997).
  • Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
  • Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice” Cancer Res 59(16):4064-4068 (Aug. 1999).
  • Hubel et al., “A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11 Suppl 5:S47-S51 (Dec 1997).
  • Iacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer,” Am. J. Clin. Oncol. 18(1):27-31 (1995).
  • IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993).
  • Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
  • “Introduction to Antibodies”, http://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007).
  • Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957).
  • Jain et M., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000).
  • Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” The Oncologist 12(9):11431150 (2007).
  • Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
  • Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996).
  • Khalili et M., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000).
  • Kildsig et al., “Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970).
  • Kirkwood et al., “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” J. Clin. Oncol. 14(1):7-17 (1996).
  • Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990).
  • Knepp et al, “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996).
  • Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures,” Phanna. Res. 15(7):1090-1095 (1998).
  • Knobler et al., “Systemic α-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984).
  • Kovacevic et al., “Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract). Abs.
  • Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-lb therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000).
  • Kronenberger et al., “Influence of interferon-α on CD82-expression in HCV-positive patients,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976).
  • Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986).
  • Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon-ω,” J. Interferon Res. 14:57-59 (1994).
  • Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996).
  • Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
  • Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).
  • Lee, “Therapy of hepatitis C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
  • Lopez et al., “Manunalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
  • Lukaszewski et al., “Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000).
  • Lund et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
  • Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997).
  • Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996).
  • Malley et al., “Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
  • Manning et al, “Stability of protein pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989).
  • Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965).
  • Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
  • McHutchison et al., “Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl J Med. 339(21):1485-1492 (Nov. 1998).
  • McHutchison et al., “Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment,” Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only).
  • Meier et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
  • Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000).
  • Milella et al., “Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C infection,” Liver 13(3):146-150 (Jun. 1993).
  • Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972).
  • Mojsov, “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992).
  • Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953).
  • Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001).
  • Nauck et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998).
  • Neumann et al., “Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998).
  • Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
  • Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Phann. Sci. 13(4).393-401 (2001).
  • Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
  • Ortiz et al., “A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids,” Biochim et Biophys Acta 898(2):214-222 (1987).
  • Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992).
  • Patzelt et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979).
  • Peterson et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990).
  • Peterson et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed), pp. 456-458, Smith-Gordon, London (1990).
  • Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973).
  • Plauth et al, “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
  • Plauth et al, “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
  • Pohl et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues,” J. Biol. Chem., 273(16):9778-9784 (1998).
  • Poynard et al., “Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211-218 (Jan. 2000).
  • Poynard et al., “Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998).
  • “Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,” Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release).
  • Quesada et al., “Interferons in Hematological Malignancies”, eds. Baron et al., U. Tex. 487-495 (1987).
  • Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997).
  • Rajkumar et al., “Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
  • Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
  • Roff et al., “Handbook of Common Polymers”, Cleveland Rubber Co. 72 pages (1971).
  • Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957).
  • Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4):554-558 (1989).
  • Roth et al., “High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999).
  • Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):6054-61 (Dec. 2007).
  • Schepp et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994).
  • Schering Corp., Intron® A for Injection, 6 pages (2001).
  • Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
  • Schmalfub et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997).
  • Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
  • Shiffman et al., “A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567).
  • Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepato). 15(3):294-299 (Mar. 2000).
  • Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000).
  • Simon et al., “A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β1a,” Neurology 55(2):185-192 (Jul. 2000).
  • Sparks et al., “Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998).
  • Sulkowski et al., “Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study,” Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236).
  • Sulkowski et al., “Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002).
  • Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001).
  • Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9):3748-56 ( Sep. 2005).
  • Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000).
  • Tong et al., “Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997).
  • Touza Rey et al., “The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000).
  • Trudeau et al., “A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer,” Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
  • Tseng et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993).
  • Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997).
  • Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006).
  • Yokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
  • Vrabec, “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
  • Wang et al., “Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000).
  • Wang et al., “Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000).
  • Wang et al., “The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000).
  • Wang et al, “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
  • Weinstock-Guttman et al., “What is new in the treatment of multiple sclerosis?” Drugs 59(3):401-410 (Mar. 2000).
  • Weissmann et al., “The interferon genes,” Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986).
  • Wright et al., “Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients,” Transplantation 53(1):121-123 (Jan. 1992).
  • Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999).
  • Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
  • Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996).
  • Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-0160 (Apr. 1989).
  • Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998).
  • Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl J. Med. 343(23):1666-1672 (2000).
  • Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover,” Hepatology 28(1):245-252 (Jul. 1998).
  • Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996).
  • Zhang et al, “A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor,” Pharm. Res. 12(10):1447-1452 (1995).
  • Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998).
  • Ziesche et al., “A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999).
  • Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages.
  • Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta® (Exenatide) Injection, rev. Oct. 2009, 34 pages.
  • Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages.
  • Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglut de [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages.
  • Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages.
  • Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages.
  • Glumetza Brochure 2009, 13 Pages.
  • Erowid,“Introduction to the Federal Controlled Substance Analog Act” 2001, 4 pages.
  • Li et al. “Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010.
  • Palmeri et al., “5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327330 (Oct. 1990).
  • Akers, et al., “Formulation Design and Development of Parenteral Suspensions,” Journal of Parenteral Science & Technology, 41(3): 88-96 (1987).
  • Alonso, et al., “Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres,” Pharmaceutical Research, 10(7):945-953 (1993).
  • Beck, et al., “Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive,” Biology of Reproduction, 28(1): 186-195 (1983).
  • Bodmeier and McGinity, “Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method,” International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988).
  • Cha and Pitt, “A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules,” Journal of Controlled Release, 7: 69-78 (1988).
  • Cha and Pitt, “The acceleration of degradation-controlled drug delivery from polyester microspheres,” Journal of Controlled Release, 8: 259-265 (1989).
  • Cohen, et al., “Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres,” Pharmaceutical Research, 8(6): 713-720 (1991).
  • Conti, et al., “Use of polylactic acid for the preparation of microparticulate drug delivery systems,” Journal of Microencapsulation, 9(2): 153-166 (1992).
  • Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953).
  • Jalil and Nixon, “Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties,” Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990).
  • Lee and Timasheff, “The stabilization of proteins by sucrose,” J. Biological Chem., 256(14): 7193-7201 (Jul. 1981).
  • Li, et al., “Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method,” Journal of Controlled Release, 37: 199-214 (1995).
  • Maa and Hsu, “Liquid-liquid emulsification by static mixers for use in microencapsulation,” Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996).
  • Maulding, et al., “Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament,” Journal of Controlled Release, 3: 103-117 (1986).
  • Mehta, et al.,“Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide),” Journal of Controlled Release, 41: 249-257 (1996).
  • Sah, et al., “A novel method of preparing PLGA microcapsules utilizing methylethyl ketone,” Pharmaceutical Research, 13(3): 360-367 (1996).
  • Sato, et al., “Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques,” Pharmaceutical Research, 5(1): 21-30 (1988).
  • Szayna, et al., “Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats,” Endocrinology, 141(6): 1936-1941 (2000).
  • Thomasin, et al., “A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation,” Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996).
  • Van Santbrink and Fauser, “Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens,” J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997).
  • Tracy et al., “Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro.” Biomaterials. 20(11:): 1057-1062 (1999).
  • Ertl et al., “Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines,” Vaccine 14(9):879-885.(1996).
  • Thompson et al., “Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone,” Journal of Controlled Release 43(1):9-22 (1997).
Patent History
Patent number: D840030
Type: Grant
Filed: Jun 2, 2016
Date of Patent: Feb 5, 2019
Assignee: Intarcia Therapeutics, Inc. (Boston, MA)
Inventors: Jay S. Smith (Wellesley Hills, MA), Michael R. Cole (Stratham, NH), Amy K. Whitson (Columbus, OH)
Primary Examiner: Ian Simmons
Assistant Examiner: Karra S Johnson
Application Number: 29/566,823